Long COVID: Biomarker and Therapeutic Discovery

Share post on social media:
Long COVID: Biomarker and Therapeutic Discovery

SEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

COVID-19 symptoms can persist in an estimated 10% of patients long past recovering from the worst impacts of acute infection and testing negative for SARS-CoV-2. Inconsistencies in symptoms, patient phenotypes, and risk factors make it difficult to pinpoint the exact cause of Long COVID. In this issue of Cayman Currents, explore prominent theories of underlying pathophysiology, lessons from other post-viral syndromes, and Cayman’s products and services to accelerate Long COVID research.

Article:

DOWNLOAD THE INFOGRAPHIC

Request your physical copy here

Cayman CurrentSEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

You might also like...

View blog
Global leader in Hepatitis E diagnostics
1 min read
Global leader in Hepatitis E diagnostics
Beijing Wantai Biological Pharmacy is a prominent supplier and well known for their range of HEV ELISA kits. Their ELISA kits are intended...
MAGicBeadTM cfDNA Isolation Kit
1 min read
MAGicBeadTM cfDNA Isolation Kit
The MAGicBead™ cfDNA Isolation Kit features a unique, magnetic bead surface chemistry that facilitates unparalleled cfDNA recovery from...
Introducing Hycult Biotech's latest antibody against Rat C5
1 min read
Introducing Hycult Biotech's latest antibody against Rat C5
Hycult Biotech is happy to introduce their new and unique blocking antibody targeting complement rat C5, now available for preclinical...